The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review
Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernandez Santander A, Howell S, Newman W, Oyee J, Walley T
Record ID 32010000281
English
Authors' recommendations:
Report found that it is not currently possible to recommend pharmacogenetic testing for CYP2D6 in women with oestrogen receptor-positive breast cancer who are receiving treatment with tamoxifen.
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/2167
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Breast Neoplasms
- Cytochrome P-450 CYP2D6
- Female
- Biomarkers, Tumor
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2011 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.